Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.

@article{OBrien2011RandomisedPI,
  title={Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.},
  author={Mary R O'Brien and Krzystof Konopa and Paul C. Lorigan and Lionel Bosqu{\'e}e and Ernest Marshall and Fr{\'e}d{\'e}rique Bustin and Sabine Margerit and Christian Fink and Jos A. Stigt and Anne Marie C Dingemans and B. B. Eldin Hasan and Jan P A M van Meerbeeck and Paul Baas},
  journal={European journal of cancer},
  year={2011},
  volume={47 15},
  pages={2322-30}
}
PURPOSE The EORTC 08062 phase II randomised trial investigated the activity and safety of single agent amrubicin, cisplatin combined with amrubicin, and cisplatin combined with etoposide as first line treatment in extensive disease (ED) small cell lung cancer (SCLC). PATIENTS AND METHODS Eligible patients with previously untreated ED-SCLC, WHO performance status (PS) 0-2 and measurable disease were randomised to 3 weekly cycles of either amrubicin alone 45mg/m(2) i.v. day(d) 1-3 (A… CONTINUE READING